Bio Therapeutic Drug Business Investment Opportunities in Sydney

Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing. - Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process. - A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions. - Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine. - Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept. - Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc. - Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients. - Positioned in the $300 billion back pain industry, addressing a significant market need. - Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development. - Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility. - Founded by individuals with decades of experience in the industry.

Our groundbreaking recombinant formulation induces stem cell recruitment and differentiation, stimulating intervertebral disc cell matrix for regeneration and self-healing. - Developed as an image-guided intra-disc administration under local anesthesia, ensuring precision and effectiveness in the therapeutic process. - A therapeutic candidate for the regeneration of spinal intervertebral discs in patients with debilitating degenerative disc conditions. - Induces the mobilization and differentiation of stem cells, leading to de novo regeneration of intervertebral discs and stabilization of the affected spine. - Backed by a compelling biological rationale and a robust preclinical data set, demonstrating a strong proof of concept. - Cure back pain with personalized, targeted, regenerative therapy via a non-invasive injection directly into the disc. - Offers a cost-effective and quick procedure, aiming to enhance the quality of life for patients. - Positioned in the $300 billion back pain industry, addressing a significant market need. - Great investment opportunity at the seed stage, with RDTI registration in Australia reflecting a commitment to research and development. - Administered as a convenient day procedure service, either in a radiology suite or a day procedure facility. - Founded by individuals with decades of experience in the industry.